Abstract
The PI3K–AKT–mTOR pathway has long been an attractive oncology target. But with top-line results from the most advanced AKT inhibitor due soon, many questions remain over which targets to hit and how to combine agents.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.